Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...

A class action lawsuit was filed against Cassava Sciences Inc. (SAVA) by Levi & Korsinsky on December 12, 2024. The ...

Cassava Sciences (SAVA)’ trial for simufilam 50 mg or 100 mg for mild-to-moderate Alzheimer’s disease, named “REFOCUS-ALZ,” has been ...

Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Ex ...

Defendants’ statements included, among other things, clear confidence in simufilam’s ability to treat Alzheimer’s Disease. On November 25, 2024, Cassava released topline results for the ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class ...

Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") of a class action securities ...

Cassava simply did not have a drug that was capable of abating the progression of Alzheimer's Disease, even when attempting to treat only the mild and moderate cases. When the true details entered ...